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ABSTRACT
Sofosbuvir has been widely adopted for Hepatitis C Virus (HCV) infection therapies
through its effect as HCV non-structured protein 5B (NS5B) inhibitor, which is
essential for HCV particle assembly. Sofosbuvir, as a prodrug, is activated through
the hydrolysis by carboxylesterase 1 (CES1) and is reported to have limited
interactions with cytochrome P450 enzymes (CYP450) and p-glycoprotein, which
results in less clinical drug-drug interactions. However, reports showed fatal or
nephrotoxic cases that utilized a co-therapy of Sofosbuvir with an anti-Human
Immunodeficiency virus (HIV) agent, tenofovir disoproxil fumarate (TDF). This
study was designed to give one explanation for these case reports. Interestingly,
although Sofosbuvir is a CES1 substrate, it covalently inhibited CES2, but not CES1,
at an IC50 of 0.8uM, which was even more potent than reported inhibition on NS5B
of HCV. Such inhibition was also proved to be caused by Sofosbuvir, but not its
metabolites.
Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF) are
prodrugs for tenofovir (TFV) in the therapies of Hepatitis B Virus (HBV) infections
and Human Immunodeficiency Virus (HIV) infections. Both of them need to be
monitored for severe hepatomegaly with steatosis. Although TDF was found to have
mitochondria-depletion induced lipid metabolism dysfunction, it was not true for TAF.
Therefore, we designed this study, trying to discover a possible explanation. Our
research found that both TAF and TDF lead to lipid retention in Huh7 cells, with
association of the induction of small heterodimer partner (SHP) expressions of both
mRNA and protein. Further experiments proved that it was the prodrugs but not TFV
that lead to the lipid retention and SHP induction. Moreover, TAF also showed a
synergic lipid retention effect with ethanol (EtOH) co-treatment, possibly caused by
the CES1-mediated ethyl transesterification pathway.
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PREFACE
This dissertation is a final work prepared as partial fulfillment for the degree of
Doctor of Philosophy of Science in the College of Pharmacy.
Manuscript 1, titled “Covalent inhibition of carboxylesterase-2 by sofosbuvir and its
effect on the hydrolytic activation of tenofovir disoproxil” was published in Journal of
Hepatology in March 2017 (66:3 660-661), and is presented here as the manuscript
format.
Manuscript 2, titled “The paradigm shift anti-hepatitis C viral agent, sofosbuvir,
covalently inhibited carboxylesterase 2 with strong clinical implications”, and
Manuscript 3, titled “Tenofovil alafenamide and tenofovir disoproxil induced lipid
accumulation in Huh7 cells through their regulations on small heterodimer partner
with interactions of ethyl alcohol”, are in preparation for publication after the
dissertation is submitted to the Graduate School of University of Rhode Island, and
they are presented here as the manuscript format.
All work supporting these three manuscripts was conducted at the University of
Rhode Island, primarily in the College of Pharmacy from September 2013 to
December 2017.
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Covalent inhibition of carboxylesterase-2 by sofosbuvir
and its effect on the hydrolytic activation of tenofovir disoproxil
Yuanjun Shen, Bingfang Yan*
Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI,
USA
Published in Journal of Hepatology, March 2017
2To the Editor:
Sofosbuvir is considered as a paradigm shift in treating hepatitis C viral infection
(HCV) [1]. Patients co-infected with human immunodeficiency virus (HIV) usually
receive both anti-HCV and antiretroviral therapy [2]. Emerging evidence, recently
reported by this and other journals, has linked sofosbuvir-containing regimens to liver
or kidney toxicity when co-administered with anti-HIV drugs [2–6]. Interestingly,
sofosbuvir and some anti-HIV drugs such as tenofovir disoproxil contain ester and/or
amide bonds. These chemical bonds are hydrolyzed by carboxylesterases. In humans,
there are two major carboxylesterases: CES1 and CES2 [7].
This study reports that sofosbuvir is a potent and covalent CES2 inhibitor. Human
liver or kidney microsomes were preincubated with sofosbuvir at 0–50 μM. The
colorimetric substrate p-nitrophenylacetate (PNPA) was subsequently added. The
hydrolysis of PNPA was monitored with a microplate-reader by an increase in the
absorbance at 400 nm [8]. The liver microsomes were pooled from 20 donors
including 12 males and 8 females. The kidney microsomes were pooled from 12
including 7 males and 5 females. As shown in Fig. 1A, sofosbuvir potently inhibited
the hydrolysis by both liver and kidney microsomes. The inhibition of kidney
hydrolysis was more profound. At 5 μM, sofosbuvir inhibited kidney hydrolysis by
82%.
The kidney predominantly expresses CES2 but not CES1 [7], and the profound
inhibition of the kidney hydrolysis suggested that CES2 was a sensitive target of
3sofosbuvir. It has been reported that sofosbuvir was a CES1 substrate [9]. These
observations pointed to the possibility that sofosbuvir inhibited CES2 through a
mechanism other than competitive inhibition. We next tested whether covalent
modification was involved in the inhibition. Liver and kidney microsomes were
incubated with sofosbuvir at 0–10 μM. The reaction mixtures were subjected to
electrophoresis (native gel) to remove unbound sofosbuvir. The gel was then stained
for carboxylesterase activity [8]. As expected, this method detected two activity bands
in liver microsomes (Fig. 1B). The activity band with the slower mobility
corresponded to CES1 and was not affected by sofosbuvir except at 10 μM (15%
inhibition). In contrast, the activity band with the faster mobility (i.e., CES2) was
drastically reduced by 1 μM sofosbuvir and completely eliminated by 10 μM (Fig.
1B). Similar observations were made on CES2 in kidney microsomes (i.e., CES2).
To shed light on the significance of the inhibition in relation to interactions with
anti-HIV drugs, lysates from CES2-transfected cells were pre-incubated with
sofosbuvir or solvent and tested for the hydrolysis of tenofovir disoproxil fumarate
(fumaric acid salt), a widely used anti-HIV agent that has been implicated in organ
toxicity with sofosbuvir [2–6]. The reactions were precipitated with acetonitrile and
analyzed by high performance liquid chromatography. As shown in Fig. 1C (top),
incubation with CES2 caused 70% conversion of tenofovir disoproxil into its
hydrolytic metabolite: tenofovir. However, the hydrolytic conversion was inhibited by
sofosbuvir. The incubations were performed at pharmacological concentrations in the
liver for both tenofovir disoproxil fumarate and sofosbuvir [5].
4Sofosbuvir is a substrate of drug transporters [10]. Therefore, it has been assumed that
sofosbuvir interacts with drugs that share these transporters. In this study, we have
demonstrated that sofosbuvir is also a potent and covalent CES2 inhibitor, providing a
novel mechanism for interactions with drugs that are CES2 substrates such as
tenofovir. Indeed, it has been reported that sofosbuvir-containing regimens increased
the blood exposure of tenofovir by as much as 98% [10]. The toxicological
consequences of the hydrolytic interactions, on the other hand, depend on the relative
toxicity between a parent drug and its hydrolytic metabolite. As for tenofovir
disoproxil, the inhibition of its hydrolysis may decrease the toxicity if its hydrolytic
metabolite is more toxic than the parent drug. In this case, organ-based hydrolysis
may come into play. For example, sofosbuvir at a certain dose inhibits liver and
kidney CES2 with the liver enzyme being inhibited to a greater extent. The blood
concentration of tenofovir disoproxil will elevate, the kidney hydrolysis will increase,
and kidney toxicity might be more evident. Alternatively, predominant inhibition of
intestinal CES2 by sofosbuvir may facilitate the absorption of tenofovir disoproxil,
leading to elevated levels of this anti-HIV drug in the liver with increased risk of
hepatic toxicity upon hydrolysis.
Another major variable is the overall activity of drug transporters for a parent drug
and its metabolite. Hydrolysis of an ester, for example, produces a carboxylic acid
species [7]. This molecular species is negatively charged at physiological conditions
and effluxed out by transporters. As a result, cells with high level expression of
5relevant transporters may not exhibit severe toxicity. Therefore, the toxicological
consequences of the hydrolytic interactions depend on the interplay between CES2
and drug transporters, and the interplay may vary depending on an organ. In addition,
sofosbuvir is commonly used together with other anti-HCV drugs, particularly with
the NS5A inhibitor ledipasvir [5]. It remains to be determined whether ledipasvir
contributed to the observed toxicity [2–5]. Nevertheless, clinical trials are required to
fully assess the pharmacological and toxicological significance of the potent and
covalent inhibition of CES2 by sofosbuvir. The authors have been actively pursuing
this possibility.
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8Figure 1. Inhibition of CES2 by sofosbuvir. (A) Inhibition of microsomal hydrolysis
by sofosbuvir microsomes for human liver (0.25 μg/per well) or kidney (1 μg/per well)
were incubated with sofosbuvir for 120 min at 0–50 μM in a total volume of 90 μL
and then 10 μL of p-nitrophenylacetate (PNPA) was added at a final concentration of
1 mM. The hydrolysis of PNPA was monitored with a microplate-reader from an
increase in the absorbance at 400 nm. (B) Native-gel electrophoresis stained for
hydrolytic activity microsomes (0.25 μg) were incubated with sofosbuvir at 0–10 μM
and subjected to native gel electrophoresis and stained for esterase activity with
4-methylumbelliferylacetate. (C) Inhibited hydrolysis of tenofovir disoproxil fumarate
lysates from CES2 transfected cells were pre-incubated with sofosbuvir at 20 μM or
the reaction buffer at 37 °C for 120 min, followed by addition of tenofovir disoproxil
fumarate at a final concentration of 20 μM. The incubations lasted for an additional
30 min and were then mixed with acetonitrile at a final concentration of 66%. The
reactions were centrifuged to remove the proteins and the supernatants were analyzed
by high performance liquid chromatography (Hitachi-300).
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The paradigm shift anti-hepatitis C viral agent, sofosbuvir, covalently inhibited
carboxylesterase 2 with strong clinical implications
Yuanjun Shen, Bingfang Yan*
Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI,
USA
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Abstract
Sofosbuvir has been widely adopted for Hepatitis C Virus (HCV) infection therapies
through its effect as a HCV non-structured protein 5B (NS5B) inhibitor, which is
essential for HCV reproduction. Sofosbuvir, as a prodrug, is activated through the
hydrolysis by carboxylesterase 1 (CES1) and was reported to have limited interactions
with cytochrome P450 enzymes (CYP450) and p-glycoprotein, which resulted in less
clinical drug-drug interactions. However, reports showed fatal or nephrotoxic cases
that utilized a co-therapy of Sofosbuvir with an anti-Human Immunodeficiency virus
(HIV) agent, tenofovir disoproxil fumarate (TDF). This study was designed to provide
one possible explanation for these case reports. Interestingly, although Sofosbuvir is a
CES1 substrate, it covalently inhibited CES2, but not CES1, at an IC50 of 0.8uM,
which was even more potent than reported inhibition on NS5B of HCV. Such
inhibition was also prove to be caused by Sofosbuvir, but not its metabolites.
Introduction
The updated report from World Health Organization (WHO) in 2017 showed that
130-150 million people worldwide has been infected by Hepatitis C virus (HCV), and
approximately 500,000 patients die because of HCV-related liver diseases each year
(WHO, 2017). Mohd Hanafiah K et al. (2013) summarized that the prevalence of
HCV infection was moderate to high in old continents, especially in China, Central
and West Asia and North Africa. After the infection of hepatocytes, the HCV
positive-sense single-stranded RNA (+ssRNA) starts to serve as a messenger RNA
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(mRNA) for translation, leading to the production of a large polyprotein, which can
be cleaved into 4 structural proteins, forming the virus particles, and 6 non-structural
(NS) proteins, essential for ssRNA translation and particle assembly (Lindenbach BD
and Rice CM, 2005). Since the 1980s, ribavirin in combination with PEGylated
interferon-alpha (PEG-IFN-α) has been used as the standard treatment, even though
with low efficacy in some HCV genotypes and potential severe side effects (Barakat
KH et al., 2013). However, with the advances in research, most newly developed
anti-HCV drugs, or so-called direct-acting antivirals (DAAs), target on four of the NS
proteins: NS3/4A, the serine protease; NS5A, the large phosphoprotein; and NS5B,
the RNA-dependent RNA polymerase (RdRp).
Since 2005, researchers has tried to design a NS5B inhibitor according to the crystal
structure of its active pocket. However, when PSI-6206 was synthesized (Clark JL et
al., 2005), it was unable to inhibit NS5B because of the difficulty to be converted into
its active triphosphate form in vivo, PSI-7409 (Clark JL et al., 2006). Therefore, a new
compound PSI-7851, the prodrug of PSI-7409, was synthesized, which has been
shown to be very potent to clear HCV in vitro (Lam AM et al., 2010). Further studies
showed that one of the diasteroisomers, PSI-7977, now named as sofosbuvir (SOF),
was even more potent than the mixture (Murakami E et al., 2010). Upon entering the
human hepatocytes, SOF is hydrolyzed by human carboxylesterase 1 (CES1) into a
carboxylate intermediate, which can be quickly metabolized into the monophosphate
nucleotide analog by histidine triad nucleotide-binding protein 1 (Hint 1). With
further catalysis by UMP-CMP kinase and nucleoside diphosphate kinase, it finally is
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converted into PSI-7409, the active triphosphate analog. SOF was considered to be
tolerant to any degree of HCV patients, because it was not metabolized by CYP
enzymes, neither did it regulate CYP expressions (Kumari R and Nguyen MH, 2015).
However, the use of SOF together with other DAA’s, with the standard of care (SOC)
treatment or with anti-human immunodeficient virus (HIV) drugs, there were quite a
few cases with hepatic and renal toxicity.
In early 2015, a group of researchers from the United Kingdom reported two cases of
severe liver toxicity associated with the use of SOF. In one of the cases, the male
patient was pretreated with anti-HIV drugs, including tenofovir disproxil fumarate
(TDF) before he was co-treated with anti-HCV drugs (SOF, Ledipasvir and Ribavirin).
After 18 days, the bilirubin level was dramatically higher than that before the
anti-HCV co-treatment. Although the therapy successfully controlled the HCV RNA
level, his liver function was severely compromised, and was continuously deteriorated
even after the interruption of anti-HCV therapy, leading to his death on day 38
(Dyson JK et al., 2016). A similar case was reported from Spain indicating that it was
because of SOF and/or Ledipasvir, but not related to the use of Ribavirin, that caused
the increase of bilirubin (Marchan-Lopez A et al., 2015). Moreover, reports also
indicated SOF-induced kidney toxicity. In 2016, a case of acute kidney injury was
reported as a 56-year-old female patient with HIV infection took Ledipasvir and SOF
together with TDF-based anti-HIV treatment, and was diagnosed with acute tubular
necrosis and acute interstitial nephritis 8 weeks after the anti-HCV treatment,
presented by the dramatically increased levels of blood urea nitrogen and serum
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creatinine (Bunnell KL et al., 2016). These reports suggested a need to have a more
cautious view on the metabolisms and potential drug-drug interactions (DDI) that
involved SOF.
In this study, we have demonstrated that SOF was an irreversible human CES2
inhibitor, which potentially explains the hepatic and renal toxicity caused by the use
of SOF in multiple drug therapies.
Materials and methods
1. Chemicals and supplies
Sofosbuvir (PSI-7977) and Tenofovir disoproxil fumurate were obtained from
MedChemExpress (Monmouth Junction, NJ). PSI-7411 ammonium salt, and
PSI-352707 ammonium salt were obtained from Toronto Research Chemicals Inc
(Toronto, Ontario, Canada). Thiazolyl blue tetrazolium bromide (MTT) and
4-methylumbelliferyl acetate (MUA) were obtained from Sigma (St. Louis, MO).
4-nitrophenol acetate was obtained from Santa Cruz Biotechnology (Dallas, TX).
Dulbecco’s modified eagle medium (DMEM) was obtained from Life Technologies
(Carlsbad, CA). The goat anti-rabbit IgG conjugated with horseradish peroxidase was
obtained from Pierce (Rockford, IL). Nitrocellulose membranes were obtained from
Bio-Rad (Hercules, CA). Expression constructs for mouse CESs were purchased from
OriGene (Rockville, MD). Mouse and rat microsomes were obtained from XenoTech
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(Kansas City, KS). Unless otherwise specified, all other reagents were obtained from
Fisher Scientific (Fair Lawn, NJ).
2. Cell culture and treatment
HEK 293FT cells were stably transfected with human CES1 and CES2 plasmid
constructs previously in our lab, and were maintained in full growth medium (DMEM,
10% FBS, 1X nonessential amino acid, and 1X penicillin/streptomycin) with
puromycin or G418 respectively. Human recombinant CES1 and CES2 proteins were
harvest from these two cell lines. Particularly, CES2 stable cells were seeded into
96-well plates (5,000/well), and were treated with SOF alone, CPT-11 alone or both
in normal medium for 48 h, and images of the cell morphology were taken by using
the Evos Imaging System. Thereafter, the medium was replaced with fresh medium
containing MTT [(4,5-dimethylthiazolyl-2)- ,5- diphenyltetrazolium bromide] at a
final concentration of 0.5 mg/ml. After a 2 h incubation at 37℃, the medium was
gently decanted, and DMSO (100 μL/well) was added to dissolve formazan product.
The optical density (OD) was determined at 570 nm, and the final OD values were
calculated by subtracting the background reading (no seeded cells).
3. Recombinant protein and enzyme activity assay
Mouse recombinant carboxylesterase proteins were collected from 293T cells
transiently transfected with the plasmids, while human recombinant carboxylesterase
proteins were collected from stably tranfected cells. The cells were rinsed by PBS and
lysed in 100mM tris buffer (pH 7.4) by a sonifier, and the cells debris was removed
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by centrifugation at 12,000g, 4℃ for 10min. The supernatants were diluted in 100mM
potassium phosphate buffer (pH 7.4) and incubated with SOF in 96-well plates for 2hr
at 37℃. Fresh 2mM nitrophenyl acetate in the potassium phophate buffer from its
acetonitrile stock solution was prepared, and 50uL of the working substrate solution
was added to each well of the 96-well plate. The kinetics of nitrophenyl acetate
hydrolysis was measured at 400nm for 15min after its addition by using SpectraMax
M2 Plate Reader.
4. Western blot
Cell lysates (2–20 μg) were resolved by 7.5% SDS - polyacrylamide gel
electrophoresis in a mini-gel apparatus (BioRad Laboratories, Hercules, CA) and
transferred electrophoretically to nitrocellulose membranes; while samples separated
by native gel electrophoresis were transfered to nitrocellulose membranes. After
nonspecific binding sites were blocked with 5% nonfat milk, the blots were incubated
with an antibody against human carboxylesterases. The primary antibodies were
subsequently localized with a secondary antibody conjugated with horseradish
peroxidase. Horseradish peroxidase activity was detected with a chemiluminescent kit
(SuperSignal West Pico; Pierce Chemical). The chemiluminescent signal was
captured by MyECL Imager.
5. Molecular modeling
To gain molecular insight regarding sofosbuvir-inhibition of CES’s as well substrates
docking, we performed molecular modeling and docking studies. The structure of
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CES2 was modeled with Discovery Studio based on the crystal structure of CES1
(3K9B; Hemmert AC et al., 2010), whose structure was retrieved from the Protein
Data Bank (www.pdb.org). Only side chain A was used, water molecules were
removed, and hydrogen atoms were added if they were missing in the original
structural file by the application of UCSF chimera (Pettersen EF et al., 2004).
Standard protonation states of the residues were adopted to produce the charged
acidic and basic side chains as well as the N- and C-termini. The homology modeling
of CES2 was also performed with Discovery Studio-client (Dassault Systèmes
BIOVIA, 2016) based on sequence similarity and the homology/analogy recognition
engine Phyre. The 3-D model of CES2 was evaluated with the “Verify Protein
(Profiles-3D)”. The CES2 homology model was then finalized by using rabbit liver
carboxylesterase structure (1K4Y; Bencharit S et al., 2002). The modeled CES2
structure was tested for the interaction with sofosbuvir with Autodock 4.2.6 (Morris
GM et al., 2009). To compare CES1 with CES2 for the residues interacting with
sofosbuvir, two major sequences of CES2 were replaced with the corresponding
sequences of CES1. The subsequent protein mutant was analyzed for the changes in
the interaction with sofosbuvir. Once again, the 3-D structure was constructed with
Discovery Studio but the interaction was determined with Autodock 4.2.6. All the
final figures of were visualized through Discovery Studio.
6. Statistics
Data are presented as mean±SD of at least three separate experiments. Statistical
significance between two means was made by one-way ANOVA followed by a
17
Tukey’s comparison test (p<0.05). Statistical analysis was performed using online
SAS OnDemand.
Results
SOF inhibited mouse ces activities in vitro. It was reported in our previous papers
that, in consideration of carboxylesterases inhibition by orlistat, mouse is a better
model compared with rat (Xiao D et al., 2013). In order to determine if this is also the
same case in this study, microsomes from mouse and rat were utilized to test the
inhibition profiles caused by SOF. First of all, mouse liver, kidney and intestine
microsomes were incubated with SOF and tested for their remaining hydrolytic
activity (Figure 1A). The SOF-induced hydrolytic inhibition was observed the most
strongly in intestine microsomes, which exhibited about an 80% decrease when
incubated with SOF at 5 μM; interestingly, however, although kidney microsome
exhibited a quicker hydrolytic activity decrease compared with the liver counterpart,
they achieved a similar end point activity (both about 60% decrease). Further
verification was based on native gel electrophoresis, which is a technique that can
preserve the activities of the proteins during separation. As suggested from the gel,
there was no SOF-induced inhibition on mouse ces1 family enzymes, ces1d and ces1e;
while mouse ces2 family enzymes, ces2c and ces2e, showed significant activity
decrease (Figure 1C). However, the enzyme inhibition in rats samples (Figure 1B, 1D)
was not as much compared with mouse. One specific point was that rat samples
exhibited more abundant Ces1 family proteins than possible Ces2 proteins, which
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might also contribute to the lower degree of inhibition compared with mouse samples.
Moreover, although rat intestine micrsome expressed a possible Ces2 family protein,
its inhibition was not as profound as its counterpart in mouse. The in vitro study not
only confirmed that mouse was a better model for CES inhibition, but also indicated
that it was ces2 family but not ces1 family that can be inhibited by SOF.
SOF inhibited ces 2 family. The in vitro data already indicated that SOF only
inhibited ces 2 family but not 1 family in microsomes. We further tested the inhibition
of enzymatic activity in recombinant mouse, rat and human CES proteins. Figure 2A
showed that mouse ces2e was significantly inhibited by SOF at the concentration of
0.1 μM, and when the concentration reached to 1 μM, both ces2c and ces2e showed
significant hydrolytic inhibition; interestingly, although ces1d kept exhibiting similar
enzyme activity compared with ces1e at the SOF concentrations of 0.1 and 1 μM,
when SOF concentration reached to 10 μM, the inhibition was also significantly
stronger than ces1e. This observation was possibly due to the competitive inhibition
of SOF as the substrate of ces 1 family enzymes. Moreover, although not shown in
microsome analysis, SOF exhibited dose-dependent enzyme inhibition in both rat
Ces1d and Ces1e, which resembled the results of mouse ces1d and ces1e, suggesting
such inhibition was also resulted from competitive inhibition (Figure 2B). Similarly,
human CES1 also showed significant but slow hydrolytic decrease after incubated
with SOF; however, the inhibition was much more significant in CES2, which
showed a 50% decrease when SOF concentration was 0.1 μM and an over 99%
decrease when SOF concentration was more than 1 μM (Figure 2C). These results
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also indicated that mouse ces1e and ces2e share similar activities with human CES1
and CES2, respectively.
Human CES2 inhibition by SOF changed cell hydrolysis ability. We next tested
whether such an inhibition on human CES2 took place in cells. The cell line chosen
for the cell survival rate assay was 293T cells transiently transfected with CES2
plasmid. Irinotecan (CPT-11) was used as the CES2 activity indicator in cells because
it can only show its cytotoxicity after its hydrolysis by CES2 into SN-38
(Humerickhouse R et al., 2000). Figure 3A showed that CPT-11 caused about 40%
decrease of cell survival rate (p<0.05), while the co-treatment of SOF with CPT-11
significantly decreased the cytotoxicity, with a cell survival rate at about 65%, which
indicated a strong in cell CES2 inhibition with SOF treatment. The cell morphology
images further confirmed the above observation in the MTT assay. Cells treated with
CPT-11 alone not only exhibited a decreased cell density, but also an altered cell
morphology; however, this morphology change was reversed by SOF co-treatment
(Figure 3B).
The human CES2 inhibition by SOF was irreversible, and the major metabolites
did not have inhibition activity. We further studied the inhibition by SOF when
CES2 was mixed with CES1. Figure 4A confirmed that CES2 was much more
sensitive to the inhibition compared with CES1; therefore, the activity decrease of the
mixture was primarily caused by the inhibition on CES2. This result was further
confirmed by native gel electrophoresis (Figure 4B). As is already known, SOF is the
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substrate of CES1. The hydrolysis of SOF leads to compound PSI-352707 (M1), and
M1 can be quickly metabolized into PSI-7411 (M2) in cells (Murakami E et al., 2010,
Figure 4E). Figure 4c showed that when SOF, M1 and M2 incubated with CES2, only
SOF was able to inhibit the enzyme activity; moreover, if SOF was incubated with
CES1 for 0.5hr or 2hr, and then incubated with CES2, the inhibition activity was
decreased (Figure 4D). Native gel electrophoresis is able to separate drugs from
enzymes if they are not bound covalently. Briefly, free or weakly bound small
molecule drugs in the electric field will be charged and quickly removed from the gel;
however, drugs that covalently bind to enzymes will stay with the protein and keep
the inhibition effect with it. In Figure 4B and 4D, the mixture of CES1 and CES2
incubated with SOF only affected the enzyme activity of CES2 but not CES1,
indicating the inhibition was caused by the covalent interaction between SOF and
CES2, regardless of the existence of CES1; in another word, SOF that escaped from
CES1 hydrolysis will covalently bind to CES2 without any further effect caused by
CES1.
CES2 may be inhibited by SOF allosterically. National Center for Biotechnology
Information (NCBI) offered the FASTA protein sequence of CES1 and CES2, with
which the Basic Local Alignment Search Tool (BLAST) on NCBI website generated
the alignment result showing that there were 97% alignment (defined as query cover),
although the sequence shared only 47% identity. SOF is the substrate of CES1;
therefore, it is not unusual to predict that SOF inhibits CES2 in its active pocket.
However, an enzyme kinetic study showed that the inhibition of SOF on CES2 was
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achieved in a non-competitive pattern, with an average Km value of 394.7±15.4 μM
measured by the rate of hydrolysis of nitrophenyl acetate (data not shown). Currently,
there is no ready-to-use CES2 computer three-dimensional model from Protein Data
Bank (PDB); therefore, we used human CES1 as the template to build the homology
model of CES2 through Discovery Studio®. This homology model was also refined
by Rabbit CES2. A docking attempt of CES2 homology structure with SOF in
Discovery Studio showed that after the entering the active pocket, SOF exhibited
more non-polar interaction in CES2 than in CES1, indicating a possible explanation
for different inhibition profiles. Moreover, the missing region 303-318 in CES2 might
be responsible for the inhibition of CES2 by SOF, which might be able to stabilize
this region in CES1 (Figure 5A and 5B). Further analysis at the sequence alignment
indicated that region 303-318 may be important for substrate-inhibitor specificity in
this case.
Discussion
SOF was reported to be metabolized mainly in the liver (Murakami E et al., 2010) and
the final inactive metabolite, GS331007, was primarily excreted by the kidneys
(Kirby BJ et al., 2015). Liver enzymes human CES1 and cathepsin A (CatA) are the
two enzymes for SOF hydrolysis; however, with a much higher abundance than CatA
in liver, CES1 is considered as the major one. CES1 mutants are common in humans,
which leads to the changes of drug metabolisms, such as oseltamivir (Zhu HJ et al.,
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2009), clopidogrel (Tang M et al., 2006) and lidocaine (Ercolani G et al., 2000). Our
study has revealed that although SOF is the substrate of CES1, as long as its prodrug
form appeared in the system, CES2 can be inhibited regardless of the existence of
CES1. Therefore, certain mutants in CES1, such as G143E (Shi Jian et al., 2016), may
be unable to hydrolyze SOF efficiently enough to stop further CES2 inhibition, which
may also explain the SOF-induced hepatotoxicity. On the other hand, the evaluation
of kidney functions are clinically determined by serum creatinine level. Generally
speaking, an increase of more than 0.3 mg/dL serum creatinine is considered as the
marker of acute kidney injury (AKI). Several clinical studies have revealed the
association between AKI and SOF related HCV therapy. Maan JFE et al. (2016)
reported that 11.2% of the patients receiving SOF experienced AKI, and among
whom only 69.2% achieved sustained virological response (SVR); however, in
patients that did not experience AKI in SOF treatment, 84.5% of them achieved SVR,
suggesting that SOF-induced AKI was also related to the decrease of anti-HCV
efficacy, possibly due to mutations of CES1. These results suggested a complicated
interplay between CES1 and CES2 in the metabolism of SOF.
Importantly, it has drawn greater concerns about the patients with HIV and HCV
coinfections, particularly because both of the viruses are bloodborne and share very
similar transmit pathways, such as sexual contact and injection drug uses.
Additionally, studies found that, compared with HIV-negative individuals,
HIV-infected patients were six times more prevalent to HCV infection, especially in
drug use groups (Platt L et al., 2016). TDF is one of the most commonly used drug
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anti-HIV therapies for co-infected patients. It is not uncommon to see renal toxicity
induced by TDF treatment, which was caused by tenofovir-induced mitochondrial
tubulopathy after the hydrolysis of TDF in situ (Moyle G, 2005; Lebrech D., et al.,
2009 ). TDF, as a prodrug, is hydrolyzed by esterases into tenofovir to exhibit its
anti-HIV activity. Clinical studies for SOF has shown a dramatic increase of TDF
plasma concentration to 1.98 (1.77-2.03) times during co-treatment compared to that
without SOF (New Zealand Medsafe, Havoni Data Sheet, 2017). Clinical reports also
associated nephrotoxicity with the combined therapy of TDF and SOF (Bunnell KL et
al., 2016). In our former study (Shen and Yan, 2016), it has been observed that TDF
was the substrate for both human CES1 and CES2, but its hydrolysis was much more
quickly catalyzed by CES2. Through our study, SOF irreversibly inhibited CES2 in
gut and liver, which could explain the elevated TDF exposure and the indicated
nephrotoxicity when TDF co-treated with SOF.
A more important issue may reside in internal circadian changes of CES. CES is
regulated by several nuclear receptors, including pregnane X receptor (PXR) and
differentiated embryo chondrocyte (DEC). For example, it was reported that the
treatment of fluoxetine in HepG2 cells lead to an decrease of PXR and an increase of
DEC1, which was related to the reduction of CES1 and CES2 expression (Shang W et
al., 2016). PXR has been long reported to regulate cytochrome P450 (CYP450)
enzymes (Bertilsson G. et al., 1998); meanwhile, its regulation of CES in rodents was
also reported (Rosenfeld J et al., 2003), although with uncertainty of its binding site
on the CES promoter region. It was not considered as a circadian gene originally;
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however, more recent evidences pointed at the opposite direct. For example,
Montagner A et al. (2016) showed that even though the change of PXR was not
profound, the downstream gene target of PXR was largely altered following a
circadian pattern. Nevertheless, DEC1 was not considered as a regulator for CES until
recently. In 2015, it was reported that mouse ces1d expression was regulated by a
stra13-involved mechanism (Chen R et al., 2015), which is equivalent to human
DEC1. Interestingly, DEC1 has been revealed to be involved in the regulation of
hepatic circadian clock by suppressing CLOCK/BMAL1-enhanced promoter activity
(Nakashima A et al., 2008). Therefore, because the expression of CES can potentially
altered through the treatment, the time of taking SOF should also be considered to
avoid stronger drug-drug interactions.
In summary, our studies have led to several important findings. First of all, we have
shown that SOF, but not its metabolites, irreversibly inhibited human CES2 but not
CES1, suggesting that SOF is a specific CES2 inhibitor. Moreover, this inhibition is
possibly caused allosterically, leading to a change in 3D shape of the active pocket
and thus resulting in the lost of hydrolytic activity. Finally, such inhibition caused by
SOF has a significant impact on drug metabolism and drug-drug interactions,
requiring closer clinical monitors for patients taking SOF.
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Figure 1. Inhibition of carboxylesterase in mouse and rat microsomes. (A) Mouse liver
(MLM), kidney (MKM) and intestine (MIM) microsomes were incubated with different
concentrations of SOF for 2hr. (B) Rat liver (RLM), kidney (RKM) and intestine (RIM)
microsomes were incubated with different concentrations of SOF for 2hr. The enzyme
activities in (A) and (B) were measured by the hydrolysis rate of nitrophenyl acetate. (C)
Mouse liver, kidney and intestine microsomes were incubated with 0.1, 1 or 10 μM of SOF
for 2hr and then were subjected to native gel electrophoresis. (D) Rat liver, kidney and
intestine microsomes were incubated with 0.1, 1 or 10 μM of SOF for 2hr and then were
subjected to native gel electrophoresis. The gels of (C) and (D) were then incubated with
4-methylumbelliferyl acetate and 1-naphthyl acetate for activity analysis.
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AMouse carboxylesterases activity B Rat carboxylesterases activity
C Human carboxylesterases activity
Figure 2. Inhibition of SOF toward recombinant proteins. Mouse (A), rat (B) and human (C)
recombinant carboxylesterases were incubated with 0.1, 1 or 10 μM for 2hr, and then the enzyme
activities were measured by the hydrolysis rate of nitrophenyl acetate. The statistics were
calculated by SAS through Posthoc-ANOVA (p<0.05).
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Figure 3. Cytotoxicity change caused by SOF. HEK-293 Cells transiently transfected with human
CES2 plasmids were treated with 3μM CPT-11 alone or together with 10μM SOF. (A) The cell
survival rate measured by MTT assay. (B) cell morphology images (20X). The statistics was
calculated by SAS through Posthoc-ANOVA (p<0.05, * represent significant difference from
DMSO treatment, and + represents significant difference from CPT-11 treatment).
DMSO CPT-11
SOF SOF+CPT-11
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Figure 4. SOF and metabolites inhibition on CES2. Human recombinant CES1 and CES2 were used
for activity inhibition tests after incubation with SOF for 30min. (A) SOF inhibited CES2 activity
activity in a dose-dependent manner in native gel electrophoresis, and only a slight inhibition of CES1
activity was observed at the highest concentration of SOF. (B) Nitrophenyl acetate hydrolysis analysis
showed that the inhibition of the mixed enzyme activity was primarily caused by the inhibition of
CES2. (C) The inhibition of CES2 activity was only achieved by SOF but not by its two major
metabolites M1 and M2. (D) SOF inhibition on CES2 was decreased if SOF was pre-incubated with
CES1 for at least 30min. (E) The metabolism of SOF.
CES2
CES1
CES2
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C Human, Mouse and Rat major CES precursor BLAST alignment (partial)
Figure 5. SOF docking profile on CES1 and CES2. SOF were docked with human CES2 homology
model (A) and human CES1 structure (B). (C) The comparison of human, mouse and rat
carboxylesterases.
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Abstract
Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF) are
prodrugs for tenofovir (TFV) in the therapies of Hepatitis B Virus (HBV) infections
and Human Immunodeficiency Virus (HIV) infections. Both of them need to be
monitored for severe hepatomegaly with steatosis. Although TDF was found to have
mitochondria-depletion induced lipid metabolism dysfunction, it was not true for TAF.
Therefore, this study was designed in an attempt to discover a possible explanation.
Results indicate that both TAF and TDF lead to lipid retention in Huh7 cells,
concomitant with the induction of small heterodimer partner (SHP) expression of both
mRNA and protein. Further experiments demonstrated that it was the prodrugs but not
TFV that led to the lipid retention and SHP induction. Moreover, TAF also showed a
synergic lipid retention effect with ethanol (EtOH) co-treatment, possibly caused by
the CES1-mediated ethyl transesterification pathway.
Introduction
Hepatitis B Virus (HBV) infections and Human Immunodeficiency Virus (HIV)
infections are two of the most significant global epidemic diseases. World Health
Organization estimated 257 million HBV carriers and 26.7 million HIV carriers
globally in 2017 (WHO). There are also about 2.7 million patients diagnosed with
co-infection of both HBV and HIV. Although HBV belongs to Orthohepadnavirus
while HIV belongs to Retrovirus, both infections can be inhibited by tenofovir (TFV),
which is on the WHO List of Essential Medicines (van Bömmel F et al., 2002; Mulato
AS and Cherrington JM, 1997). TFV functions as a nucleotide analogue in HBV
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therapy, while it is also a nucleotide reverse transcriptase inhibitor (NtRTI) in HIV
therapy. However, the poor permeability of TFV due to the two negative charges
limited its clinical use (JP Shaw et al., 1997), and, therefore, prodrugs of TFV have
been developed to improve its pharmacokinetics profile. TFV disoproxil fumarate
(TDF) and TFV alafenamide fumarate (TAF) are two of the successful oral prodrugs.
TDF, commercially Viread, has been approved for treatment of both chronic HBV
infection and HIV-1 infection (Viread, FDA, 2012); on the other hand, TAF,
commercially Vemlidy, is only approved for HBV treatment but not recommended
for HIV-1, which is because of its risk to enhance development of HIV resistance
(Vemlidy, FDA, 2017). Both reagents are formed as an ester structure so as to
increase the permeability. TAF and TDF can be hydrolyzed both by Cathepsin A
(CatA) in peripheral blood mononuclear cell (PBMC) or carboxylesterase (CES) in
liver (Birkus G et al., 2016), and the hydrolysis of the esters releases their parent
compound, TFV, which is further metabolized into the active format,
TFV-diphosphate (TFV-DP) (Balzarini J et al., 1998). However, use of both the
approved drugs required clinical monitoring of severe hepatomegaly with steatosis.
Carboxylesterases (CES) belong to a family of hydrolases. The most abundant of CES
in human tissues are CES1 and CES2 (Bencharit et al., 2002), which are closely
related to both drug metabolisms and lipid dispositions (Redinbo et al., 2003; Ruby
MA et al. 2017). CES enzymes play a vital role in the activation of both TAF and
TDF; however, the hydrolysis was reported to be responsible to renal and hepatic
toxicity (Samuels R et al., 2017). Interestingly, CES1 has been suggested to be largely
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involved in lipid metabolism (Xiao D et al., 2012). Therefore, the drug disposition of
TAF and TDF with the involvement of CES becomes increasingly important both for
clinical monitoring and for future drug discoveries.
This study has been designed to broaden the understanding of the mechanisms of the
lipid retention caused by TAF and TDF treatment in cells, including gene regulation
and drug-drug interactions. It was found that both TAF and TDF were able to
significantly increase lipid retention, especially in CES knockout cells prepared by the
Clustered Regularly Interspaced Short Palindromic Repeats(CRISPR)/Cas9
transfection technique.
Materials and methods
1. Chemicals and supplies
Tenofovir disoproxil fumurate and tenofovir alafenamide fumurate were obtained
from MedChemExpress (Monmouth Junction, NJ). Dulbecco’s modified eagle
medium (DMEM) was obtained from Life Technologies (Carlsbad, CA). The goat
anti-rabbit IgG conjugated with horseradish peroxidase was obtained from Pierce
(Rockford, IL). Nitrocellulose membranes were obtained from Bio-Rad (Hercules,
CA). Unless otherwise specified, all other reagents were obtained from Fisher
Scientific (Fair Lawn, NJ).
2. Cell culture and treatment
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Huh7 cells were maintained in full growth medium (DMEM, 10% FBS, 1X
nonessential amino acid, and 1X penicillin/streptomycin). After seeded in plates or
chamber slides, treatment agents were dissolved (1:1000) in 1% delipid DMEM
medium. Cells were either collected for protein and messenger RNA extraction after
two days of TAF or TDF treatment, or stained with nile red and DAPI for lipid
droplet fluorescent assay after one day of TAF or TDF treatment and another day of
anti-viral and oleic acid co-treatment. Mouse primary hepatocytes were isolated from
Balb-c mice through hepatic perfusion by William’s Medium E (WME) with
collagenase. Cells were separated by centrifugation with Percoll, and seeded with
WME with insulin, transferrin, selenium (ITS) and dexamethasone (DEX). Seeded
Human primary hepatocytes in 24 well plates were purchased from Thermo Fisher.
3. CRISPR cell line preparation
CRISPR/Cas9 plasmids were purchased from Santa Cruz (Dallas, TX) and their 20-nt
sequences guiding RNA are presented in Table 1. The plasmids were transfected into
Huh7 cells, and then cells were sorted by the cytofluorometry according to the
expression of GFP conducted at Life Span. Inc (Providence, RI). Single colonies were
then picked up after the sorting, and examined by SDS-PAGE or Native Gel
Electrophoresis for the expressions of target proteins.
4. Western blot
Cell lysis was sonicated in Tris-HCl buffer (pH 7.4), and the same amount of total
protein measured by commercial bicinchoninic acid assay were resolved by 7.5%
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SDS - polyacrylamide gel electrophoresis in a mini-gel apparatus (BioRad
Laboratories, Hercules, CA) and transferred electrophoretically to nitrocellulose
membranes. After nonspecific binding sites were blocked with 5% nonfat milk, the
blots were incubated with an antibody against human or mouse small heterodimer
partner (SHP). The primary antibodies were subsequently localized with a secondary
antibody conjugated with horseradish peroxidase. Horseradish peroxidase activity was
detected with a chemiluminescent kit (SuperSignal West Pico; Pierce Chemical). The
chemiluminescent signal was captured by MyECL Imager.
5. Immunocytochemistry
Huh7 cells (4X104/well) were seeded in four-well chamber slides. After two-day
treatment, cells were rinsed in ice-cold PBS, and fixed by 4% formaldehyde in PBS
for 10min. Fixed cells were then permeabilized and blocked by incubating with 0.1%
Triton-X and 1% BSA in PBS for 1hr. SHP primary antibody (NR0B2 antibody,
abx001518, Abbexa, Cambridge, UK) was dissolved 1:100 with 1% BSA in PBS, and
incubated with the cells overnight at 4℃. Afterwards, Alexa Fluor® 488 goat
anti-rabbit IgG antibody 4ug/mL (1:500) in PBS were incubated with cells and
imaged at 10X and 20X by Invitrogen EVOS FL Auto Cell Imaging System.
6. Lipid droplet fluorescent assay
Huh7 cells 8000/well were seeded in 96-well clear bottom white microplates. After
one day of treatment with TAF or TDF, cells were co-treated with anti-viral agents
and 400uM oleic acid for another day. Cells were then fixed by 4% formaldehyde in
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PBS and stained by nile red and DAPI for imaging (Invitrogen EVOS FL Auto Cell
Imaging System) as well as fluorescent signal measurements (SpectraMax M2
Multi-Mode Microplate Reader).
7. Statistics
Data are presented as mean±SD of at least three separate experiments. Statistical
significance between two means was made by one-way ANOVA followed by a
Tukey’s HSD comparison test. Statistical analysis was performed by adopting
R-Studio.
Results
TAF and TDF induced more lipid retention than TFV in Huh7 cells. It has been
showed that chronic use of quite a few NtRTIs lead to mitochondrial damage, which
may end up causing hepatic steatosis (Day L et al., 2004). TDF and TAF both
potentially lead to severe hepatomegaly with steatosis (Viread lable, FDA, 2012;
Vemlidy label, FDA, 2017). In this study, we managed to mimic the lipid retention in
Huh7 cells following treatment with TDF or TAF. First of all, treatment of TFV, the
metabolite, did not exhibit significant increase of lipid retention even at the highest
concentration (Figure 1A) the lipid droplet microscopy also verified the reading
results (Figure 1E). However, both TAF (Figure 1B and 1F) and TDF (Figure 1C and
1G) showed strong elevation of lipid retention compared with control, which also
exhibited in a dose dependent manner for both treatments. Interestingly, compared to
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DMSO treatment, TDF treatment in each concentration resulted in higher mean value
of lipid retention readings than those from TAF treatments, although the statistic
analysis showed similar trends.
TAF and TDF increased SHP expression both on mRNA level and protein level.
Tests were designed to determine the possible reason for the lipid retention. In 2006,
it was reported that ob/ob mice with SHP-/- had significantly lower lipids level
compared with ob/ob groups (Huang J, 2006). Result here also suggest that both TAF
and TDF treatments lead to a dose dependent mRNA and protein expression elevation
of SHP, which was not observed in TFV treatment (Figure 2A-2C). The mRNA
showed a moderate dose-dependent manner in TAF treatment, and the level did not
show statistic difference until the concentration of TAF reached 10μM (Figure 2B); in
contrast, TDF showed more profound SHP mRNA elevation even at 5μM (Figure 2C).
However, protein analysis showed that TAF treatment resulted in a more profound
expression than TDF treatment. The immunocytochemistry results also strongly
suggested that the treatments of TAF and TDF, but not TFV, lead to an increase of
SHP expression around the nucleus (Figure 2D). Interestingly, It was clear that, in
TAF treatment, SHP expressed mostly in nucleus, which overlapped nicely with
DAPI staining, a dye that only stain the nucleus, but TDF treatment seemed to show a
more diffused expression of SHP.
SHP played a vital role in lipid retention in Huh7 cells. To determine if the lipid
retention in Huh7 cells was also regulated by SHP, Huh7 cells were transfected with
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SHP plasmids transiently and then treated with oleic acid for one day. The lipid
droplet assay results showed there was a significant increase (30%, p<0.05) in
SHP-transfected Huh7 cells compared with wild type cells (Figure 3A), which was
also showed in the microscopy images (Figure 3B). These results confirmed that SHP
played a vital role in the lipid accumulation effect in Huh7 cells.
The pro-drug, but not the metabolite, induced lipid retention. The direct TFV
treatment showed no induction in lipid retention, nor did it regulate SHP expression;
however, TFV was known to have poor cell membrane permeability (Shaw JP et al.,
1997), which led to the development of the current two prodrugs. Therefore,
experiments were designed with CRISPR CES-knockout (CES-KO) cell lines to test
the effect of the prodrug metabolism in the cells on lipid accumulation profile. TAF
treatment resulted in much higher lipid accumulations in CES1-KO cells (Figure 4B)
compared with WT cells (Figure 4A) in all treatment concentrations; however, it was
not that significant in CES2-KO cells (Figure 4C). On the other hand, TDF treatments
resulted in higher lipid accumulation in both CES1-KO and CES2-KO cells (Figure
4D-4F); however, these increased lipid retention effects were less significant than
those from TAF treatment in CES1-KO cells. These results reflect the fact that TAF
was a substrate of CES1 but not CES2, while TDF was a substrate for both enzymes.
Interestingly, CES2-KO cells exhibited higher base-line lipid retention than
CES1-KO cells.
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The cotreatment of TAF and ethyl alcohol lead to synergic lipid retention in
Huh7 cells. Ethanol (200mM) treatment in Huh7 cells generally caused 25% increase
in lipid accumulation (Figure 5A-C). Additionally, similar to previous results, the
increased concentrations of TAF resulted in a 3-36% increase of lipid accumulation.
Moreover, the co-treatment of TAF with ethanol lead to a 40-63.5% increase in lipid
accumulation, representing a synergic effect with a saturation from 5 μM TAF
treatment (Figure 5A-D). It is well known that CES1 not only functions as a hydrolase,
but also functions as a transesterase when alcohol is involved (Brzezinski MR et al.,
1997; Fleming CD et al., 2005; Hu ZY et al., 2014). In order to understand the
possible mechanisms of this synergic effect, TAF, ethanol and liver microsomes from
different species were co-incubated and the mixture was subjected to HPLC analysis.
It was clear that all the three microsomes were able to generate a new peak (retention
time 2.1min) apart from TAF (retention time 2.8min) and TFV (retention time
1.2min), especially from rat liver microsome. This new peak was hypothesized to be
ethyl-transesterified TAF. It was also shown that CES1 family activity was higher in
rat, than mouse and human (Figure 5E-G).
Discussion
Our current study is the first to illustrate the fact that it was the prodrugs, but not TFV,
that caused profound lipid retention in Huh7 cells. Similar results were also observed
in HepG2 and HC04 cell lines (data not shown). Instead of concluding that the
prodrugs directly induced lipid retention through their up-regulation effects on human
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SHP, it is still highly possible to be related to the poor permeability of TFV. Taneva E
et al. (2016) suggested that the permeability of TDF was 104 folds higher than TFV,
and was at least a 10-fold increase of drug uptake in tested cell lines than TFV as well.
Studies showed that most of TAF and TDF molecules were able to pass the
membrane through passive diffusion; however, TFV was primarily transported by
human organic anion transporter (OAT)-1 and OAT-2, which required energy and
exhibited less efficiency. A well known mechanisms of TFV toxicity is its capability
to induce mitochondria dysfunction, which results in decreased mitochondria DNA
(mtDNA), increased reactive oxygen species and decreased β-oxidation (Apostolova
N et al., 2011). However, with a much higher permeability, TDF hydrolysis in
mitochondria is predicted to be more efficient than the transportation of TFV from
cytosol.
Lipid is efficiently oxidized by mitochondria in liver through β-oxidation. It was
found that TDF treatment caused oxidative stress with increased measurements of
thiobarbituric acid reacting substances (TBARS) and decreased reduced glutathione in
rats (Abraham P et al., 2013). TDF treatment also showed to deplete mtDNA, which
is essential for the formation of the respiratory chain (Samuels R et al., 2017). Both
oxidative stress and mtDNA depletion were considered to be the reasons for reduced
β-oxidation. Thus, the lipid retention induced by TFV prodrugs was first explained by
their toxicity in mitochondria. However, Gilead scientists reported that TAF was not
able to deplete mtDNA in human T-cell lines (Stray KM et al., 2017), although
clinical reports also mentioned higher levels of all lipid fractions in TAF than in TDF
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treated human subjects (Sax PE et al., 2015). Therefore, it becomes increasingly
important to understand mechanisms that lead to lipid retention other than
mitochondria toxicity.
This is the first study to show that treatment with TAF and TDF, but not TFV,
increases SHP expressions in both mRNA and protein levels. Although more studies
need to be done to understand if it was the hydrolysis of prodrugs after their entry into
the nucleus, or it is the prodrug themselves, that causes the up-regulation of SHP, it
became clearer that such mechanisms could be added to the β-oxidation dysfunction
theory for the explanation of lipid retention. Huang JS et al. (2007) reported that the
over expression of SHP in OB-/- mice was the leading cause of hepatic steatosis.
When SHP gene was knocked out from such mice, liver weight, lipid accumulation in
tissue histological analysis, and hepatic triglycerides were all significantly decreased.
Further research from the same lab also revealed that SHP correlated with neuronal
PAS domain-containing protein 2 (NPAS2) in mice in lipid metabolism regulation
(Lee SM et al., 2015). Other research also indicated that the involvement of farnesoid
X receptor (FXR) together with SHP in the regulation of lipid metabolisms (Kim KH
et al., 2017). It is not clear about the mechanisms of lipid regulation by SHP, but the
increase of SHP by TAF and TDF from our study was highly related to the lipid
retention observed in Huh7 cells. More importantly, such up-regulation of SHP was
more profoundly and steadily observed when cells were treated with TAF than with
TDF in all type of cells that we adopted, which also explained why TAF therapy also
caused steatosis without reported function in mtDNA depletion.
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Additionally, alcohol consumption is also a great concern for HIV patients. In 2014, a
group of researchers reported that 62.9% of the HIV patients with certain anti-virus
treatment were reported to have worse medical problems caused by drinking (Elliott
JC et al., 2014). Likewise, a systematic review also indicated that 77% of the studies
showed negative impact on HIV therapy by alcohol use, in which 14 out of 17 studies
focused on alcohol consumption and HIV suppression also concluded in a negative
association (Vagenas P et al., 2015). Interestingly, alcohol not only caused toxicity in
liver and kidneys, but also played very important roles in drug metabolism. Reports
has shown that CES1 was able to catalyze its substrate, with the existence of ethyl
alcohol, into an ethyl ester. For example, methylphenidate, a CES1 substrate for
attention-deficit/hyperactivity disorder therapy,if taken by adolescent with alcohol
abuse, was transesterified into ethylphenidate (Patrick KS et al., 2014). Other CES1
substrates were also found to be ethyl transesterified with alcohol consumption, such
as cocaine and cocaethylene (Brzezinski MR et al., 1997), fatty acids and fatty acyl
ethyl esters (Fleming CD et al., 2005), and clopidogrel and ethyl clopidogrel (Hu ZY
et al., 2014). Similarly, our research also showed that TAF, while co-incubated with
ethanol, can be potentially transesterified by liver microsomes, where abundant CES1
was expressed. Although the pharmacological effect of possible ethyl-TAF was not
clear, it is very likely that this hypothesized ethyl-TAF may be involved in lipid
metabolism dysfunction. However, more research need to be done to verify the
structure of the molecule and its pharmacological effects as well. It is also interesting
to notice that the ethyl-ester transesterification effects were comparable between
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mouse and human liver microsome, but not rat, indicating a possible animal model for
in vivo studies.
In conclusion, TAF and TDF exhibited potent lipid retention activity through the
up-regulation of SHP both in mRNA and in protein level, which could be synerically
enhanced with ethyl alcohol.
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Table 1. Guiding RNA of CRISPR plasmids (Santa Cruz, Dallas, TX)
Name gRNA Sense sequence
CES1
GTGCGGCATCAACCTATGAT
TCACATCTGCTATCAAGTCC
TGTTGTCCTGGACCCAGCGC
CES2
CCATGAAGGCTCTAACCTGC
CCTCTTTACTCTTGCCCCGC
CAAAAACAAGCGCACCACCG
SHP
CCCGTAGCCGCTGCCTATGT
CGGGCCGGTGCTGCCTACAT
CCGTGAGGAGGACACGGGTC
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Figure 1. Lipid retention in Huh7 cells by treating with TFV, TAF and TDF. Huh7
cells were seeded 8000/well in black 96-well plates with clear bottom. Cells were
treated with different concentrations of TFV, TAF and TDF for the first day, and then
were treated together with 400 μM Oleic Acid for the second day. The cells were then
fixed, washed by PBS, and stained by 5 μM Nile red and 5 μM DAPI. The
fluorescence intensity was measured by plate reader and the images were taken by
EVOS Microscope. (A) Lipid retention of TFV treatment is represented by
fluorescence intensity. (B) Lipid retention of TAF treatment is represented by
fluorescence intensity. (C) Lipid retention of TDF treatment is represented by
fluorescence intensity. (D) Image of DMSO treatment. (E) Image of TFV 10uM
treatment. (F) Image of TAF 10uM treatment. (G) Image of TDF 10uM treatment.
The statistics was calculated by R-Studio through Post hoc - ANOVA (**represents
p<0.01).
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Figure 2. SHP regulation by treatment of TFV, TAF and TDF in Huh7 cells. Huh7
cells were seeded in 24-well plates, and then treated with different concentrations of
TFV, TAF and TDF for two days. One part of cells were then lysated by RNA Bee for
mRNA collection. Complimentary DNA were prepared from the collected mRNA by
RT-PCR, and then SHP mRNA expression was measured through Taqman probes by
qPCR with GAPDH as the control. The other part of cells were washed by PBS and
sonicated in 100mM Tris-HCl to collect protein. Protein samples were then subjected
to 7.5% SDS-PAGE and Western Blot for SHP protein level analysis with GAPDH as
the internal control. Huh7 cells were also seeded on 8-well chamber slides at 2X104
cell/well, and then treated with the same strategy. Cells were then fixed, washed by
PBS, permeablized by 0.1% Triton-X and blocked by 1% BSA in PBS for 3 hr, and
then incubated with SHP primary antibody over night. Slides were stained by DAPI
and Alexa Fluor® 488 conjugated Goat anti-Rabbit IgG, and images were taken by
EVOS microscope. (A) TFV activity on SHP expression in mRNA and protein levels;
(B) TAF activity on SHP expression in mRNA and protein levels; (C) TDF activity
on SHP expression in mRNA and protein levels; (D) ICC images of the changes of
SHP (green) and nucleus (blue) with different concentrations of anti-viral reagents.
The statistics was calculated by R-Studio through Post hoc - ANOVA (*represents
p<0.05, and **represents p<0.01).
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Figure 3. Lipid retention in Huh7 cells with SHP transfection. SHP plasmids were
transiently transfected to Huh7 cells, and cells were then reseeded into black 96-well
plates with clear bottom. (A) Cells were treated with 400 μM Oleic Acid for one day,
and lipid retention was presented by the florescence intensity. (B) Images were taken
to further confirm the results in wild type Huh7 and SHP-Huh7. The statistics were
calculated by R-Studio through Post hoc - ANOVA (*represents p<0.05).
60
A B C
D E F
Figure 4. Lipid retention profiles in CRISPR screened Huh7 cells. CES1 KO and
CES2 KO Huh7 cells were prepared by the transfection of targeting gene
CRISPR/Cas9 plasmids and the selection by flow cytometry. (A) Wild type Huh7
cells were treated with different concentrations of TAF, and lipid retention was
presented by the fluorescent intensity of nile red staining. (B) CES1 KO Huh7 were
treated with different concentrations of TAF, and lipid retention was presented by the
fluorescent intensity of nile red staining. (C) CES2 KO Huh7 were treated with
different concentrations of TAF, and lipid retention was presented by the fluorescent
intensity of nile red staining. (D) Wild type Huh7 cells were treated with different
concentrations of TDF, and lipid retention was presented by the fluorescent intensity
of nile red staining. (E) CES1 KO Huh7 were treated with different concentrations of
TDF, and lipid retention was presented by the fluorescent intensity of nile red staining.
(F) CES2 KO Huh7 were treated with different concentrations of TDF, and lipid
retention was presented by the fluorescent intensity of nile red staining. The statistics
was calculated by R-Studio through Post hoc - ANOVA (*represents p<0.05, and
**represents p<0.01).
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Figure 5. Lipid retention profile of TAF treatment in Huh7 cells co-treated with
alcohol. (A) Huh7 cells were co-treated with 1μM TAF and 200mM EtOH, and the
lipid retention was presented by the fluorescent intensity of Nile red. (B) Huh7 cells
were co-treated with 5μM TAF and 200mM EtOH, and the lipid retention was
presented by the fluorescent intensity of Nile red. (C) Huh7 cells were co-treated with
10μM TAF and 200mM EtOH, and the lipid retention was presented by the
fluorescent intensity of Nile red. (D) Images of the treatments with TAF alone in
different concentrations, EtOH alone, and the co-treatments. Mouse (E), Rat (F) and
Human (G) liver microsomes (0.2 μg/μL) were incubated with 400mM EtOH and 400
μM TAF in 37°C for 90 min, and the mixtures were subjected to HPLC analysis. The
statistics was calculated by R-Studio through Post hoc - ANOVA (*represents p<0.05,
and **represents p<0.01).
